Goldman Sachs Group Inc vs Revvity Inc — how do they compare? Goldman Sachs Group Inc trades at $895.32 (market cap $256.98B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Goldman Sachs Group Inc is far larger — about 15.1× Revvity Inc's market cap, and Goldman Sachs Group Inc pays the higher dividend (2.27%). Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Revvity Inc for 12 Days on average.
| GS | RVTY | |
|---|---|---|
Market Cap | $256.98B | $16.98B |
Volume | 1,748,426 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $1.15K | $157.36 |
52-Week Low | $744.60 | $82.26 |
Typical Hold Time | 101 Days | 12 Days |
Enterprise Value | $814.98B | $19.30B |
Dividend Yield | 2.27% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $882.59, down 0.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong profitability with a 31.68% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights CEO David Solomon's focus on expanding earnings and building a durable revenue base, while the FICC business is expected to soften in Q3 2026.
The stock presents a mixed outlook: attractive valuation with a P/E of 13.63 and consensus price target of $1,130 suggests upside, but negative operating cash flows and high debt levels pose risks. Analyst sentiment is cautious with 40% buy ratings, while institutional interest remains steady. Key catalysts include revenue growth in asset and wealth management, but macroeconomic volatility and competitive pressures could hinder performance.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →